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Yes-associated protein 1 (YAP1) is a key effector molecule regulated by the Hippo pathway
and described as a poor prognostic factor in breast cancer. Tumor protein 53 (TP53) muta-
tion is well known as a biomarker related to poor survival outcomes. So far clinical character-
istics and survival outcome according to YAP1 and TP53 mutation have been poorly
identified in breast cancer.
Patients and methods
Retrospectively, 533 breast tumor tissues were collected at the Seoul St Mary’s hospital and
Gangnam Severance Hospital from 1992 to 2017. Immunohistochemistry with YAP1 and
p53 specific antibodies were performed, and the clinical data were analyzed.
Results
Mutant p53 pattern was associated with aggressive tumor features and advanced anatomi-
cal stage. Inferior overall survival (OS) and recurrence free survival (RFS) were related with
mutant p53 pattern cases with low nuclear YAP1 expression (P = 0.0009 and P = 0.0011,
respectively). Multivariate analysis showed that mutant p53 pattern was an independent
prognostic marker for OS [hazard ratios (HR): 2.938, 95% confidence intervals (CIs):
1.028–8.395, P = 0.044] and RFS (HR: 1.842, 95% CIs: 1.026–3.304). However, in cases
with high nuclear YAP1 expression, there were no significantly difference in OS and RFS
according to p53 staining pattern.
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Conclusion
We found that mutant p53 pattern is a poor prognostic biomarker in breast tumor with low
nuclear YAP1 expression. Our findings suggest that interaction between nuclear YAP1 and
p53 expression pattern impact survival outcomes.
1. Background
Yes-associated protein 1 (YAP1) is a key downstream effector molecule of the Hippo pathway.
The Hippo pathway is a central regulator of organ size and tissue homeostasis. In addition,
YAP1 is involved in the control of cell proliferation, stem cell maintenance, metastasis, apopto-
sis, and tumor differentiation [1–6]. Activated YAP1 is generally considered to be an oncogene
in diverse solid cancers [7–9], but there is still controversy regarding the role of YAP1 of breast
cancer [10, 11]. The p53 protein is functionally inactivated in most of the human malignancies
due to both alterations in its regulatory pathways and mutations that directly affect the tumor
protein 53 (TP53) gene [12, 13]. Moreover, mutations of the TP53 is associated with poor sur-
vival outcome in solid cancers including breast cancer [14, 15]. Critical for function of tumori-
genesis is the ability of mutant p53 protein to be engaged in aberrant molecular interactions
that lead to dramatic alterations in gene expression. In several studies, mutant TP53 has been
shown to interact with several transcription factors such as nuclear transcription factor Y, ste-
rol regulatory-element binding proteins, specificity protein 1, and vitamin D receptor [16–19].
YAP1 physically interacts with mutant p53 proteins in breast cancer cells and mutant TP53
enhanced pro-proliferative transcriptional activity such as cyclin A, cyclin B, and cyclin depen-
dent kinase 1 genes [20].
However, the clinical characteristics and survival outcomes according to nuclear YAP1 and
p53 co-expression in breast cancer have been poorly explored. The aim of this study was to
explore clinical characteristics and survival outcomes of patients with breast cancer according
to the expression level of nuclear YAP1 and p53 protein expression pattern.
2. Material and methods
2.1. Patients
We retrospectively collected tumor tissues from patients undergoing primary curative sur-
gery for breast cancer at the Gangnam Severance Hospital in Seoul, Korea from February
1992 to April 2017 and at the Seoul St Mary’s hospital in Seoul, Korea from March 2012 to
October 2017. Enrolled patients were underwent curative surgery with histologically con-
firmed invasive breast cancer (stage Ⅰ to Ⅲ). All patient treatments were performed accord-
ing to standard protocols. Clinical data including age at surgery, tumor size, lymph node
status, histological grade (HG), status of estrogen receptor (ER), status of progesterone
receptor (PR), status of human epidermal growth factor receptor-2 (HER2), lympho-vascu-
lar invasion (LVI), treatment modalities, recurrence, and death. Tumor HG was determined
by applying the modified Scarff-Bloom-Richardson grading system. The median age in this
study was 50 years (range, 14–86 years). All procedures performed in studies involving
human participants were in accordance with the ethical standards of the institutional and/
or national research committee and with the 1964 Helsinki Declaration and its later amend-
ments or comparable ethical standards. The study protocol was approved by the institu-
tional review board (IRB) of the Gangnam Severance Hospital (local IRB No. 3-2019-0188)
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and St Mary’s hospital (Local IRB number: KC17TNSI0414). The need for informed con-
sent was waived under the approval of the IRB due to the retrospective design. All data was
completely anonymized prior to analysis. Patients’ medical records were assessed from 1995
to 2015.
2.2. Immunohistochemistry staining and interpretation
As previously described [21], 3-μm thick tissue sections were cut from formalin-fixed paraf-
fin-embedded (FFPE) tissue microarray (TMA) blocks. After deparaffinization and rehy-
dration with xylene and alcohol graded solutions, respectively, immunohistochemistry
(IHC) was performed by using a Ventana Discovery XT Automated Slide Stainer (Ventana
Medical System, Tucson, AZ, USA). Cell Conditioning 1 buffer (citrate buffer, pH 6.0; Ven-
tana Medical System) was used for antigen retrieval. The slices were incubated with primary
antibody against p53 (1:300, clone DO-7; Novocastra, Leica Biosystems, Newcastle Upon
Tyne, UK), YAP1 (1:200, clone 63.7, Santa Cruz Biotechnology, Dallas, Texas, USA), ER
(ER; 1:150, clone 6F11; Novocastra), PR (PR; 1:100; clone 16; Novocastra), HER2 (1:1500,
DAKO, Glostrup, Denmark, clone polyclonal). The appropriate positive and negative con-
trols were included.
2.2.1 Molecular subtyping. Nuclear staining values of 1% or higher were considered
indicative of ER and PR positivity [22]. HER2 staining was interpreted based on the 2018
American Society of Clinical Oncology/College of American Pathologists guidelines [23].
Only samples with strong and circumferential membranous HER2 immunoreactivity (3+)
were considered as positive, while those with 0 and 1+ HER2 staining were regarded as nega-
tive. Cases with equivocal HER2 expression (2+) were further evaluated for HER-2 gene ampli-
fication by silver in situ hybridization (SISH). Breast cancer subcategorization was based on
the results of IHC staining for ER, PR, HER2, as well as the SISH results for HER2. The speci-
mens were categorized as follows: i) Luminal/HER2-negative (ER- and/or PR-positive and
HER2-negative); ii) HER2-positive (HER2-positive regardless of ER and PR status); iii) triple
negative breast cancer (TNBC; ER-, PR-, and HER2-negative).
2.2.2. Interpretation of YAP1 and p53 immunohistochemistry. As previously described
[24], tumors with negative and weak (1+) nuclear YAP1 staining were considered low YAP1
tumors, while high YAP1 tumors were defined as moderate (2+) and strong (3+) nuclear
YAP1 expression (Fig 1).
The p53 IHC was interpreted as two mutant patterns and wild type pattern [25, 26] (Fig 2):
1. nonsense mutation pattern: completely absence of expression (0%)
2. missense mutation pattern: diffuse and strong expression (>60% of tumor cell nuclei)
3. wild type pattern: focal and weak expression
2.3. Statistical analysis
Overall survival (OS) was defined as the period from the date of curative primary surgery
to the end of follow-up or death due to any cause. Recurrence free survival (RFS) was
defined as the period from the date of primary surgery to the date of any recurrence (loco-
regional and/or distant metastasis) of breast cancer, death due to any cause or the last fol-
low-up. The data of patients who did not exhibit relevant events were censored at the end
of follow-up.
Continuous variables between two groups were compared using the Student’s t-test or the
Mann-Whitney test. Categorical variables were compared by using the Chi-square test or the
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Fisher’s exact test. Survival curves were obtained by the Kaplan-Meier method and two-group
comparisons were performed by log-rank test. The uni- and multivariate Cox proportional
hazard models were used to identify factors associated with survival outcome (OS and RFS).
The variables used in the multivariate analysis were those that showed statistical significance
in the univariate analysis.
Statistical analysis was performed by using SPSS version 24 (SPSS: Chicago, IL, USA) soft-
ware. Statistical significance was defined as a p-value less than 0.05, and a 95% confidence
intervals (CIs) not including 1.
Fig 1. Immunohistochemical analysis of nuclear YAP1 expression. IHC analysis was evaluated in high-power fields
(400x magnification) by an experienced pathologist. The sample were classified as negative (a), 1+ (b), 2+ (c), and 3+
(d), based on the intensity of YAP1 nuclear staining.
https://doi.org/10.1371/journal.pone.0250986.g001
Fig 2. Expression pattern of p53. (Left) Mutant p53 pattern was defined when tumor completely loss of p53
expression or more than 60% of tumor cells had nulear p53 expression. (Right) Except for mutant p53 pattern, various
random expression ranged from 1% to 59% of p53 nuclear expression was considered as wild-type expression pattern.
https://doi.org/10.1371/journal.pone.0250986.g002
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3. Results
3.1. Impact of p53 mutation on the baseline characteristics of patients with
nuclear YAP high/low breast cancer
A total of 553 breast cancer patients at Gangnam Severance Hospital and Seoul St Mary’s Hospi-
tal were included in this study. Low and high nuclear YAP1 expression was found in the tumors
of 445 (80.5%) and 108 (15.5%) patients, respectively. Among 553 cases, 411 (74.3%) had wild-
type p53 pattern, 142 (25.7%) had mutant p53 pattern, respectively. The clinical characteristics
between patients in these two groups according to nuclear YAP1 expression were compared in
Table 1. Mutant p53 pattern with low nuclear YAP1 expression was associated with aggressive
tumor features, including ER negativity, PR negativity, high HG, aggressive subtype (TNBC),
larger tumor size, receipt of chemotherapy, radiotherapy, and/or endocrine therapy. Mutant
p53 pattern with high nuclear YAP1 expression also was related to aggressive feature, including
ER negativity, PR negativity, high HG, LVI, receipt of chemotherapy, and endocrine therapy.
Among 553 patients, 275 patients underwent p53 sequencing and IHC assay at the same
time. In cases with wild-type p53 pattern IHC (n = 209), there was no mutation by p53
sequencing (S1 Table). In cases with mutant p53 pattern IHC (n = 66), 54 cases (81.8%)
showed TP53 mutation by sequencing analysis (including missense, non-sense, and frameshift
mutation etc.). Among remaining twelve, three had TP53 mutations of uncertain significance
and nine had wild-type TP53.
3.2. Prognostic significance of nuclear YAP1 expression
At a median follow-up time of 59 months (range, 0–325 months), 74 experienced recurrences.
Among them, 49 had distant metastasis and 31 had loco-regional recurrences (including dupli-
cation). There were a total of 24 deaths.
Among the low YAP1 tumors, mutant p53 pattern showed a significantly decreased OS
compared to those with wild-type p53 patterns [Fig 3A; hazard ratios (HR) 6.688; 95% confi-
dence intervals (CIs) 2.187–20.45, P = 0.0009]. Tumors with mutant p53 patterns were also
had a significantly poorer RFS compared to those with wild-type p53 pattern (Fig 4A; HR
2.771; 95% CIs 1.501–5.115, P = 0.0011).
However, among the high YAP1 tumors, OS (Fig 3B; HR 0.972; 95% CIs 0.198–4.774,
P = 0.9718) and RFS (Fig 4B; HR 0.3596; 95% CIs 0.113–1.145, P = 0.0835) were not differed
between mutant and wild-type p53 pattern.
In the univariate Cox proportional hazard model, ER, PR, HG, LVI, mutant p53 pattern,
receipt of radiotherapy, and receipt of endocrine therapy were significantly associated with an
inferior OS in low YAP1 tumors (Table 2; HR 4.751, 95% CIs 1.726–13.073; P = 0.003). After
adjustment of these factors, the multivariate Cox proportional hazard model revealed that
mutant p53 pattern was a significantly independent prognostic factor for OS in low YAP1
tumors (Table 2; HR 2.938, 95% CIs 1.028–3.395, P = 0.044).
In the univariate analyses of RFS in low YAP1 tumors, ER, PR, HG, LVI, receipt of endo-
crine therapy, and mutant p53 pattern were significant factors of poor RFS (Table 3; HR 2.444,
95% CIs 1.448–4.126, P = 0.001). Multivariate analysis confirmed mutant p53 pattern was sig-
nificantly associated with poor RFS in low YAP1 tumors (Table 3; HR 1.842, 95% CIs 1.026–
3.304, P = 0.041).
4. Discussion
In present study, we identified that mutant p53 pattern was a significant prognostic factor in
breast cancer with low nuclear YAP1 expression (OS, HR 6.688, 95% CIs 2.187–20.45,
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Table 1. Clinical characteristics in relation to nuclear YAP1 expression and p53 expression pattern.
Nuclear YAP1 Low Nuclear YAP1 High
WT p53 pattern, n = 329,
(%)
Mutant p53 pattern, n = 116,
(%)
P value WT p53 pattern, n = 82,
(%)
Mutant p53 pattern, n = 26,
(%)
P value
Age (year, mean±SD) 51.42±11.12 51.90±11.51 0.692 49.79±9.46 50.15±9.28 0.865
ER <0.001 0.009
Positive 210 (63.8) 23 (19.8) 32 (39.0) 3 (11.5)
Negative 119 (36.2) 93 (80.2) 50 (61.0) 23 (88.5)
PR <0.001 0.046
Positive 181 (55.0) 16 (13.8) 26 (31.7) 3 (11.5)
Negative 148 (45.0) 100 (86.2) 56 (68.3) 23 (88.5)
HER2a 0.147 0.446
Positive 34 (10.3) 18 (15.5) 9 (11.0) 1 (3.8)
Negative 291 (88.4) 98 (84.5) 73 (89.0) 25 (96.2)
Missing 4 (1.2) 0 0 0
HGa <0.001 <0.001
I, II 210 (63.8) 27 (23.3) 50 (61.0) 4 (15.4)
III 114 (34.7) 89 (76.7) 31 (37.8) 21 (80.8)
Missing 5 (1.5) 0 1 (1.2) 1 (3.8)
Subtypea <0.001 0.010
Luminal/HER2(-) 200 (60.8) 18 (15.5) 31 (37.8) 3 (11.5)
HER2 (+) 32 (9.7) 18 (15.5) 9 (11.0) 1 (3.8)
TNBC 93 (28.3) 80 (69.0) 42 (51.2) 22 (84.6)
Missing 4 (1.2) 0 0 0
Tumor size 0.010 0.162
�2 cm 179 (45.4) 47 (40.5) 38 (46.3) 8 (30.8)




Negative 221 (67.2) 75 (64.7) 53 (64.6) 17 (65.4)
Positive 107 (32.5) 41 (35.3) 28 (34.1) 9 (34.6)
Missing 1 (0.3) 0 1 (1.2) 0
LVIa 0.293 0.004
Negative 245 (74.5) 80 (69.0) 59 (72.0) 11 (42.3)
Positive 73 (22.2) 31 (26.7) 18 (22.0) 13 (50)
Missing 11 (3.3) 5 (4.3) 5 (6.1) 2 (7.7)
Chemotherapy a <0.001 0.006
Done 187 (57.4) 96 (82.8) 53 (64.6) 24 (92.3)
Not done 139 (42.6) 19 (16.4) 29 (35.4) 2 (7.7)
Missing 3 (0.9) 1 (0.9) 0 0
Radiotherapy a 0.010 0.091
Done 186 (56.5) 82 (70.7) 38 (46.3) 17 (65.4)
Not done 140 (42.6) 34 (29.3) 44 (53.7) 9 (34.6)
Missing 3 (0.9) 0 0 0
Endocrine therapy <0.001 0.005
Done 227 (69.0) 24 (20.7) 34 (41.5) 3 (11.5)
Not done 100 (30.4) 92 (79.3) 48 (58.5) 23 (88.5)
Missing 2 (0.6) 0 0 0
WT, wild-type; SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; HG, histological grade;
TNBC, triple negative breast cancer; LVI, lymph-vascular invasion.
aPercentages calculated without missing values.
https://doi.org/10.1371/journal.pone.0250986.t001
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P = 0.0009; RFS, HR 2.771, 95% CIs 1.501–5.115, P = 0.0011), and interestingly, mutant p53
pattern showed no prognostic effect on high YAP1 tumors.
As a downstream effector of the dysregulated Hippo pathway, activation or overexpression
of YAP1 contributed to tumor progression in diverse solid tumors including lung cancer [27],
bladder cancer [8], ovarian cancer [28], and gastric cancer [29]. However, in breast cancer, the
role of YAP1 has been still considered controversial. One study reported the no significant role
of YAP1 [30], and the others showed that YAP1 was the favorable predictor, and functioned as
a tumor suppressor in breast cancer [31–33]. Conversely, there were also studies that described
YAP1 as a poor prognostic factor mediating tumor development and progression of breast
cancer [34–36].
Recent study identified that nuclear localization of YAP1 is an activated form of YAP1 [2,
37]. Disruption of the Hippo pathway lost the inhibitory effects on YAP1 and transcriptional
coactivator with PDZ-binding motif (TAZ), another Hippo transducer, and results in nuclear
retention of YAP1/TAZ. Nuclear-localized YAP1/TAZ binds transcriptional enhanced
Fig 3. Kaplan-Meier survival curves of OS in according to presence of p53 mutation with low/high nuclear YAP1 expression. In
patients with low nuclear YAP1 expression, p53 mutation pattern exhibited poor OS than p53 wild-type pattern (a, HR 6.688, 95% CIs
2.187–20.45, P = 0.0009, log-rank test). However, in patients with high nuclear YAP1 expression, p53 mutation pattern was not
significantly different OS than p53 wild-type (b, HR 0.972, 95% CIs 0.198–4.774; P = 0.9718, log-rank test).
https://doi.org/10.1371/journal.pone.0250986.g003
Fig 4. Kaplan-Meier survival curves of RFS in relation to presence of p53 mutation with low/high nuclear YAP1 expression. In
patients with low nuclear YAP1 expression, p53 mutation pattern exhibited inferior RFS than p53 wild-type pattern (a, HR 2.771, 95%
CIs 1.501–5.115, P = 0.0011, log-rank test). However, in patients with high nuclear YAP1 expression, p53 mutation pattern was not
significantly different OS than p53 wild-type pattern (b, HR 0.3596, 95% CIs 0.113–1.145; P = 0.0835, log-rank test).
https://doi.org/10.1371/journal.pone.0250986.g004
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associate domain (TEAD), and regulates gene transcription related to multiple cancer-associ-
ated features [38]. Recent study found that YAP1 activation resulted in fatty acid oxidation
and developed lymph node metastasis in mouse model [6].
TP53 is one of the most common mutated gene in many cancers, and studies showed the
crosstalk between TP53 and YAP1 [20, 39]. In breast cancer, TP53 mutation has been known
to be associated with hormone receptor negativity, high HG, and poor prognosis [40, 41],
which is in line with our result. Previous study showed that mutant TP53 and YAP1 shared a
common transcriptional signatures, increased expression of cyclin A, cyclin B, cell division
Table 2. Uni- and multivariate analysis for overall survival in patients with low nuclear YAP1 expression tumors.
Univariate analysis Multivariate analysis
HR (95% CIs) P value HR (95% CIs) P value
Age (continuous) 1.006 (0.962–1.053) 0.784
ER 0.006 0.873
Negative Reference Reference
Positive 0.127 (0.029–0.557) 0.722 (0.013–39.536)
PR 0.022 0.542
Negative Reference Reference





Ⅰ, Ⅱ Reference Reference
Ⅲ 1.897 (1.077–3.340) 0.625 (0.161–2.429)
Tumor size 0.115
�2 cm Reference
>2 cm 2.341 (0.813–6.738)





Positive 7.406 (2.571–21.334) 6.157 (2.117–17.905)
P53 mutation 0.003 0.044
Wild type Reference Reference





Not done Reference Reference
Done 4.583 (1.041–20.177) 2.459 (0.540–11.203)
Endocrine therapy 0.003 0.047
Not done Reference Reference
Done 0.105 (0.024–0.462) 0.211 (0.046–0.978)
HR, hazard ratio; CIs, confidential intervals; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; HG, histologic grade;
LVI, lymph-vascular invasion.
https://doi.org/10.1371/journal.pone.0250986.t002
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cycle 25C, and cyclin-dependent kinase 1 genes [20]. Previous study thus suggested that YAP1
activation could further enhance the effect of mutant TP53, and showed the worst disease-spe-
cific survival in mutant TP53 with high YAP1 signature score in METABRIC dataset in breast
cancer patient [20]. This study showed sequential survival difference by YAP1 and TP53 status,
most favorable survival from wild-type TP53/low YAP1 to wild-type TP53/high YAP1—
mutant TP53/low YAP1—mutant TP53/high YAP1. This study had strength in using the
molecular data of TP53 and YAP1 status. However, the number of patients was relatively
small, and the breast cancers according to molecular subtype were not defined.
Table 3. Uni- and multivariate analysis for recurrence-free survival in patients with low nuclear YAP1 expression tumors.
Univariate analysis Multivariate analysis
HR (95% CIs) P value HR (95% CIs) P value
Age (continuous) 1.005 (0.981–1.029) 0.709
ER 0.003 0.051
Negative Reference Reference
Positive 0.430 (0.248–0.746) 0.538 (0.288–1.003)
PR 0.009 0.946
Negative Reference Reference





Ⅰ, Ⅱ Reference Reference
Ⅲ 1.309 (1.006–1.704) 0.869 (0.439–1.719)
Tumor size 0.143
�2 cm Reference
>2 cm 1.479 (0.876–2.495)





Positive 1.858 (1.053–3.281) 1.653 (0.931–2.935)
P53 mutation 0.001 0.041
Wild type Reference Reference







Endocrine therapy 0.013 0.453
Not done Reference Reference
Done 0.515 (0.305–0.869) 1.552 (0.492–4.894)
HR, hazard ratio; CIs, confidential intervals; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; HG, histologic grade;
LVI, lymph-vascular invasion.
https://doi.org/10.1371/journal.pone.0250986.t003
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In this study, we focused on the effect of YAP1 and p53 expression pattern on breast can-
cer, with the largest number of breast cancer patient cohort. In present study, case with
mutant p53 pattern showed significantly worse OS and RFS among the low YAP1 tumors.
Furthermore, mutant p53 pattern was the independent poor prognostic factor in low YAP1
tumors. Intriguingly, there was no statistical difference of OS or RFS depending on the p53
expression pattern in high YAP1 tumors. The RFS graph appeared to be separated, but did
not reach the statistical significance. Moreover, the graph was reversed compared to the low
YAP1 tumors.
So far, the connection of the Hippo pathway and p53 family proteins has been recognized,
but still needs further investigation. In normal state, the Hippo pathway and p53 cooperate as
tumor suppressors. Meanwhile, as described above, YAP1 and mutant TP53 could enhance
the proliferative effect of each other [20]. Raj et al. deeply discussed the reciprocal crosstalk
between Hippo and p53 pathways that interacts in many levels and are closely coordinated
[42]. Under wild-type TP53, YAP1 is tightly regulated but loss of TP53 function causes uncon-
trolled oncogenic activity of YAP1. Also, upstream regulators of both TP53 and YAP1, MDM2
and large tumor suppression 1 (LATS1), could adjust cellular function of PTPN14 that further
affects the Hippo pathway signaling. In glioblastoma and breast cancer cells, mutant TP53
establish its oncogenic activity by WASP-interacting protein (WIP), and WIP stabilizes YAP/
TAZ thereby sustaining the cancer stem cell survival and oncogenic function [43]. Conversely,
loss of LAST 1/2, upstream inhibitor of YAP1, led to conformational change of wild-type
TP53, and made similar functional state of mutant TP53 by affecting the TP53 interactome
[44]. This change increased YAP1 activity with upregulation of prostaglandin-endoperoxide
synthase 2, one of the TP53 target gene, in breast cancer cells [44]. Our non-significant OS and
RFS in high YAP1 tumors, those with wild-type p53 pattern might act as functional mutant
p53-like state, and that might lead the no differences according to the p53 expression pattern.
Our study has several limitations. First and the most critical limitation is that the p53
expression pattern was determined by immunohistochemistry. In sequencing result, TP53
mutation was not detected in 18.2% of cases with mutant pattern IHC. However, some cases
but not all cases that had p53 mutant pattern IHC had mutation pattern on IHC was not con-
sistent with all mutations on TP53 sequencing, all wild0type pattern did not have significant
TP53 mutation in sequencing (S1 Table). In addition, there has been studies that correlated
the mutation status of TP53 and p53 IHC [26, 45]. However, other confirmative method such
as Sanger sequencing would have promised more accurate data and results. One of our result–
no difference of survivals of high YAP1 tumors depending p53 expression pattern–also might
be originated from this limitation. Second limitation is the small number of high YAP1
tumors. RFS appeared to be separated according to the p53 status in high YAP1 tumors com-
pared to the low YAP1 tumors, although not significant. If the number of high YAP1 tumors
were large enough as low YAP1 tumors, survival analysis might have been significantly sepa-
rated by p53 expression pattern, or showed converted results. As YAP1 and TP53 have
reported to interact closely in previous mechanical studies, further study with larger number
of high YAP1 tumors is required to verify the association between high YAP1 and mutant
TP53. One clinical study with advanced gastric cancer revealed that activated YAP1 along with
mutant TP53 status led better survival outcomes, which explained by upregulated proliferative
activity of tumor as well as chemosensitivity [46]. As patients in our cohort also treated with
standard protocol including appropriate adjuvant chemotherapy, this might explain the trend
of superior RFS of mutant p53 pattern and high YAP1 tumors. In addition, TMA slide staining
may underestimate the heterogeneity of the tumor compared to whole-slide examination.
Despite these limitations, we found relevant evidence showing specific correlations of survival
outcomes between YAP1 and p53 expression status.
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5. Conclusions
In this study, we tried to find the prognostic effect and association of p53 and YAP1 expression
pattern in breast cancer. Mutant p53 pattern was strong prognostic factor in low YAP1 tumors
but in high YAP1 tumors, that effect seemed to be disappeared. Since real-world clinical data
with YAP1 and p53 expression pattern is lacked, further investigation should be performed to
evaluate the possible potential of both YAP1 and TP53 as therapeutic targets.
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